



[Home](#)

2. [FDA PI](#)

3. [Neo-Poly-Dex](#)

Neo-Poly-Dex: Package Insert / Prescribing Info

Package insert / product label

Generic name: [neomycin sulfate, polymyxin b sulfate, and dexamethasone](#)

Dosage form: ophthalmic ointment

Drug class: [Ophthalmic steroids with anti-infectives](#)

[Medically reviewed](#) by Drugs.com. Last updated on Mar 25, 2025.

On This Page

[Description](#)

[Clinical Pharmacology](#)

[Indications and Usage](#)

[Contraindications](#)

[Warnings](#)

[Precautions](#)

[Patient Counseling Information](#)

[Adverse Reactions/Side Effects](#)

[Dosage and Administration](#)

[How Supplied/Storage and Handling](#)


[Storage and Handling](#)

(Sterile)

Rx only


Neo-Poly-Dex Description

Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment USP is a multiple dose anti-infective steroid combination in a sterile ointment for topical application. The active ingredient dexamethasone, is represented by the following structural formula:




C₂₂H₂₉FO₅ Mol. Wt. 392.47

Neomycin Sulfate is the sulfate salt of neomycin B and C which are produced by the growth of *Streptomyces fradiae* Waksman (Fam. Streptomycetaceae). It has a potency equivalent to not less than 600 micrograms of neomycin base per milligram, calculated on an anhydrous basis. The structural formulae are:



The structural formulae are:



PRESERVATIVES ADDED: Methylparaben 0.05%, Propylparaben 0.01%.

Neo-Poly-Dex - Clinical Pharmacology

Corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow the healing. Since corticoids may inhibit the body's defense mechanism against infections, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.

When a decision to administer both a corticoid and an antimicrobial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered, plus assured compatibility of ingredients when both types of drugs are in the same formulation and, particularly, that the correct volume of drug is delivered and retained.

The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.

Indications and Usage for Neo-Poly-Dex

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain cases of infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical radiation or thermal burns; or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drugs in this product is active against the following common bacterial eye pathogens: *Staphylococcus aureus*, *Escherichia coli*, *Haemophilus influenzae*, *Klebsiella/Enterobacter* species, *Neisseria* species, *Pseudomonas aeruginosa*.

This product does not provide adequate coverage against *Serratia marcescens*, and Streptococci, including *Streptococcus pneumoniae*.

Contraindications

Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular structures. Hypersensitivity to a component of the medication. (Hypersensitivity to the antibiotic component occurs at a higher rate than for other components.)

Warnings

NOT FOR INJECTION. Do not touch tube tip to any surface, as this may contaminate the contents. Prolonged use may result in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection. If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients.

Products containing neomycin sulfate may cause cutaneous sensitization.

Employment of steroid medication in the treatment of herpes simplex requires great caution.

Precautions

General

The initial prescription and renewal of the medication order beyond 8 grams should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.

The possibility of persistent fungal infections of the cornea should be considered after prolonged steroid dosing.

Information for Patients:

Do not touch tube tip to any surface, as this may contaminate the contents.

Pregnancy:

Pregnancy Category C. Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose.

In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.

There are no adequate or well-controlled studies in pregnant women. Neomycin, Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.

Nursing Mothers:

Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Neomycin, Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment, is administered to a nursing woman.

Pediatric Use:

Safety and effectiveness in pediatric patients have not been established.

Adverse Reactions/Side Effects

Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.

Reactions occurring most often from the presence of the anti-infective ingredients are allergic sensitizations. The reactions due to the steroid component are: elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.

Secondary Infection: The development of secondary infection has occurred after use of combinations containing steroids and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion must be considered in any persistent corneal ulceration where steroid treatment has been used.

Secondary bacterial ocular infection following suppression of host responses also occurs.

Neo-Poly-Dex Dosage and Administration

Apply a small amount into the conjunctival sac(s) up to three or four times daily, or may be used adjunctively with Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension at bedtime.

How to apply Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment:

1. Tilt your head back.

2. Place a finger on your cheek just under your eye and gently pull down until a "V" pocket is formed between your eyeball and your lower lid.
3. Place a small amount (about 1/2 inch) of Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment in the "V" pocket. Do not let the tip of the tube touch your eye.
4. Look downward before closing your eye.

Not more than 8 grams should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in [PRECAUTIONS](#) above.

How is Neo-Poly-Dex supplied

Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment USP is supplied in an ophthalmic tube in the following size:

3.5 gram tube – Prod. No. 04034

Storage:

Store between 15°-30° C (59°-86° F).

KEEP OUT OF REACH OF CHILDREN.

DO NOT USE IF CAP AND NECKRING ARE NOT INTACT.

FOR OPHTHALMIC USE ONLY.

Revised November 2007

Bausch & Lomb Incorporated


Tampa, FL 33637

©Bausch & Lomb Incorporated

9114000 (Folded)

9114100 (**Flat**)

Principal Display Panel



NDC 11695-1436-6

NEO-POLY-DEX

Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment USP

Rx only

STERILE

Net wt. 1/8 oz. (3.5g)

Reorder No. 002600

Distributed Exclusively by:

Butler AHS Dublin, OH 43017

OPHTHIMAL

NEO-POLY-DEX

neomycin sulfate, polymyxin b sulfate, and dexamethasone ointment

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:11695-1436
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
NEOMYCIN SULFATE (UNII: 057Y626693) (NEOMYCIN - UNII:I16QD7X297)	NEOMYCIN SULFATE	3.5 mg in 1 g
POLYMYXIN B SULFATE (UNII: 19371312D4) (POLYMYXIN B - UNII:J2VZ07J96K)	POLYMYXIN B SULFATE	10000 [USP'U] in 1 g
DEXAMETHASONE (UNII: 7S5I7G3JQL) (DEXAMETHASONE - UNII:7S5I7G3JQL)	DEXAMETHASONE	1 mg in 1 g

Inactive Ingredients

Ingredient Name	Strength
LANOLIN (UNII: 7EV65EAW6H)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
MINERAL OIL (UNII: T5L8T28FGP)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
PETROLATUM (UNII: 4T6H12BN9U)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:11695-1436-6	1 in 1 CARTON		
1		3.5 g in 1 TUBE		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA064063	07/25/1994	

Labeler - Butler Animal Health Supply (017880659)

Registrant - Bausch & Lomb Incorporated (196603781)

Establishment

Name	Address	ID/FEI	Business Operations
Bausch & Lomb Incorporated		807927397	MANUFACTURE

More about Neo-Poly-Dex (dexamethasone / neomycin / polymyxin b ophthalmic)

- [Check interactions](#)
- [Compare alternatives](#)
- [Reviews \(7\)](#)
- [Side effects](#)
- [Dosage information](#)
- [During pregnancy](#)
- [Drug class: ophthalmic steroids with anti-infectives](#)

Professional resources

- [Neo-Poly-Dex Eye Drops prescribing information](#)

Other brands

[Maxitrol](#)

Other formulations

- [Poly-Dex ophthalmic](#)

Related treatment guides

- [Conjunctivitis, Bacterial](#)
- [Blepharitis](#)
- [Keratitis](#)
- [Uveitis](#)
- [Keratoconjunctivitis](#)

[Medical Disclaimer](#)

DRUG STATUS

Availability

Rx Prescription only

[Pregnancy & Lactation](#)

 Risk data available

CSA Schedule*

N/A Not a controlled drug

WADA Class

o/o Anti-Doping Classification



User Reviews & Ratings

[7 Reviews](#)

Drugs.com Mobile App

Access drug & treatment information, identify pills, check interactions and set up personal medication records.



About

[About Drugs.com](#)

[Advertising policy](#)

[Attribution & citations](#)

Terms & privacy

[Terms of use](#)

[Editorial policy](#)

[Privacy policy](#)

Support

[Help center](#)

[Sitemap](#)

[Contact us](#)



[Subscribe to our newsletter](#) for the latest medication news, new drug approvals and FDA alerts.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated 7 Apr 2025), Cerner Multum™ (updated 13 Apr 2025), ASHP (updated 10 Apr 2025) and others.



Ad Choices
ADVERTISEMENT



Copyright © 2000-2025 Drugs.com. All rights reserved.